WE ARE ON A MISSION

TO UNLOCK THE POWER OF CELLULAR SIGNALING WITH LOW-DOSE THERAPEUTICS TO SAFELY TACKLE THE WORLD'S TOUGHEST HEALTH CHALLENGES

Nanodose Therapeutics is a global leader in developing recombinant proteins. We believe that the answer to solving chronic conditions is not "never" but rather "not yet".

We are united in a shared vision to defeat chronic health conditions that frustrate clinicians, debilitate patients, sadden caregivers and cost society. We are champions in the pursuit of scientific excellence and the importance of the scientific method. We are bold and challenge each other so that we can restore hope to the community we serve.

OUR VISION

WE ENVISION A WORLD WHERE ONE DAY OUR PATIENTS CAN EXPECT MORE FROM LIFE BECAUSE OF OUR VALUABLE TREATMENTS.

What Drives Us...

The thought that one day our treatments will help even just one patient
That all chronic conditions are possible to be treated, we just haven’t discovered yet how to do that
By focusing on the patient, we will always do what’s right
Operating in a professional manner with the ethics and behavior that is expected of a biotech leader
The belief that the power of nanodosing and cellular signaling can bring the efficacy AND the safety to help patients

OUR VALUES

We believe the secret sauce for creating patient solutions comes from the culture that we create inside our organization. It is through the values that we hold as our foundation to build that culture. At the heart of Nanodose Therapeutics is an unwavering belief that we can and need to make a remarkable impact in patients’ lives. It’s what motivates every day and it shows in our actions.

We are not content with the status

quo. We take pride in dreaming about and looking for the next innovation that can help and equip patients to tackle the hardest conditions. It is our boldness and disregard for the status quo that motivates us to want and achieve more. This allows us to bring new and better products to patients – faster.

We look

for what's possible

We prioritize developing and

delivering effective medications that address chronic conditions with a focus on practical outcomes and patient well-being. We embrace cutting-edge research and technology to accelerate progress and ensure that every initiative moves towards tangible, impactful outcomes.

We are focused on results

By focusing on the power

of many versus the power of one,

we can leverage the unique strengths and talents of others to find solutions for tough healthcare and development challenges. We welcome disagreement, diverse thought, and conflict as these are the building blocks for growth and the best possible output. We’re not just content from having a team – we value the high-performing team.

We ensure safety and integrity

OUR STRATEGY

We are focused on developing our lead candidate oSLO (oxidized streptolysin O) for the treatment of chronic Traumatic Brain Injury (cTBI). We believe that it has the potential to become an important treatment that can help the millions of people who suffer from its devastating effects. We believe that this recombinant protein can also help the millions of patients who suffer from Alzheimer’s Disease and Stroke. Nanodose Therapeutics owns the worldwide rights for development and commercialization for oSLO.

What is
oSLO?

Learn More

STRATEGIC IMPERATIVES

BRING OSLO INTO THE CLINIC

A major goal for oSLO (NT-101) is to ensure that the product is in the clinic in 2024. The company intends to submit an Investigational New Drug (IND) application to the FDA and then to start a Phase I study to determine the safety and dosing for oSLO in healthy volunteers.

DEVELOP ADDITIONAL FORMULATIONS FOR OSLO

Currently we are developing oSLO using 10mL dropper bottle for the use in cTBI. We are also developing other formulations of the NT-101 product to allow for patient satisfaction, consistency and standardization. Moreover, with our next generation product NT-203 for cTBI, we have an opportunity to provide lifecycle and collaboration opportunities.

DEVELOP OSLO FOR ADDITIONAL INDICATIONS

We believe oSLO can address other neurological conditions such as Alzheimer’s We believe oSLO can address other neurological conditions such as Alzheimer’s Disease and Stroke. We believe it also has potential for other indications outside of Neurology with opportunities in COPD and wound healing.

SEEK STRATEGIC PARTNERSHIPS

We look for strategic partnerships with biopharmaceutical companies, academic institutions, and non-profit organizations to develop and commercialize oSLO. These partnerships could provide significant funding to advance the development of oSLO and allow us to benefit from expertise of our partners.

PREPARE MCC FOR THE CLINIC FOR HEDS

By finalizing our pre-clinical work, our intention is to file an IND in early 2025 and begin clinical testing of our MCC compound for the treatment of Hypermobile Ehlers-Danlos syndrome to help patients to reduce the painful and debilitating dislocations of joints.